Market Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 0.5% at midday, while the Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 0.3%. The CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index both saw a 0.1% increase, whereas the CSI Innovative Drug Industry Index declined by 0.2% [1]. Company Developments - Recently, CloudTop New Medicine announced that the U.S. FDA has approved its cardiovascular product, Lurepirdine injection, for lowering low-density lipoprotein cholesterol levels in patients with hypercholesterolemia. The company plans to submit a listing application in the Greater China region in the first half of 2026, which is expected to boost market confidence in the internationalization prospects of innovative drugs [1].

Group 1 - The pharmaceutical sector experienced narrow fluctuations, with the Hang Seng Innovative Drug Index down by 0.1%, while other indices such as the CSI Hong Kong Pharmaceutical and Health Comprehensive Index and the CSI Biotech Theme Index both rose by 0.1% [1] - The CSI Innovative Drug Industry Index saw an increase of 0.2%, indicating a positive trend in innovative drug stocks [1] - Recent fund inflows into ETFs indicate continued investment interest, with the Hang Seng Innovative Drug ETF and Pharmaceutical ETF receiving net inflows of 97 million yuan and 370 million yuan respectively over the past week [1] Group 2 - The index focuses on leading stocks in the Hong Kong medical and health industry, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other pharmaceutical sectors [3] - The Innovative Drug ETF tracks the CSI Innovative Drug Industry Index, which includes no more than 50 companies primarily engaged in innovative drug research and development [4][5] - The Biotech ETF tracks the CSI Biotech Theme Index, which consists of up to 50 companies involved in gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [6][8] Group 3 - The CSI Biotech Theme Index recorded a slight increase of 0.1% at midday [7] - The CSI Pharmaceutical and Health Industry Index, which includes companies from the CSI 300 Index in the pharmaceutical sector, also rose by 0.1% [12][13]

Core Insights - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 8.3% this week, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 6.9% [1] - The pharmaceutical sector has shown a significant structural recovery trend after a prolonged period of valuation adjustment, with continued innovation in drug development expected in the second half of the year [1] Index Performance - The weekly performance of various indices is as follows: - Hang Seng Innovative Drug Index: +8.3% - CSI Hong Kong Medical and Health Comprehensive Index: +6.9% - CSI Innovative Drug Industry Index: +2.9% - CSI Biotechnology Theme Index: +2.3% - CSI 300 Medical and Health Index: +1.6% [2] - The rolling P/E ratios for these indices are: - Hang Seng Innovative Drug Index: 60.6x - CSI Hong Kong Medical and Health Comprehensive Index: 29.2x - CSI Innovative Drug Industry Index: 52.2x - CSI Biotechnology Theme Index: 57.3x - CSI 300 Medical and Health Index: 31.8x [2] Valuation Insights - The valuation percentiles as of July 10, 2023, are: - Hang Seng Innovative Drug Index: 46.0% - CSI Hong Kong Medical and Health Comprehensive Index: 76.7% - CSI Innovative Drug Industry Index: 68.7% - CSI Biotechnology Theme Index: 52.3% [2] - The indices have shown varying performance over different time frames, with the Hang Seng Innovative Drug Index up 90.2% year-to-date and 88.8% over the past year [6] ETF Tracking - There is one ETF tracking the Hang Seng Innovative Drug Index, four ETFs for the CSI Hong Kong Medical and Health Comprehensive Index, seven for the CSI Innovative Drug Industry Index, and four for the CSI Biotechnology Theme Index [4]

Group 1 - The core viewpoint of the news is that innovative drug stocks in the Hong Kong market have shown strong performance, with notable increases in share prices for several companies [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Index rose by 4.7%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increased by 3.7% [1] - In the A-share market, the CSI Innovative Drug Industry Index rose by 2.2%, and both the CSI Biotechnology Theme Index and the CSI 300 Pharmaceutical and Health Index increased by 1.7% [1] Group 2 - The Biotech ETF (No. 159837) tracks the CSI Biotechnology Theme Index, which focuses on leading biotech companies in the A-share market, with a rolling P/E ratio of 58.0 times and a valuation percentile of 70.7% [4] - The Medical ETF (ONLY 512010) tracks the CSI 300 Pharmaceutical and Health Index, covering major companies in the pharmaceutical and health industry, with a rolling P/E ratio of 31.3 times and a valuation percentile of 49.3% [4]

Group 1 - The pharmaceutical sector experienced a broad increase today, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index rising by 2.6%, the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index increasing by 2.4%, the CSI Innovative Drug Industry Index up by 0.7%, the CSI Biotechnology Theme Index rising by 0.6%, and the CSI 300 Pharmaceutical and Health Index increasing by 0.2% [1] - According to Wind data, the pharmaceutical ETF (512010) has seen a net inflow of over 600 million yuan over the past seven trading days [1] - China Galaxy Securities noted that the pharmaceutical sector has undergone a significant structural repair trend after a prolonged valuation adjustment, with continued innovation in drug business development expected in the second half of the year [1] Group 2 - The indices mentioned focus on leading companies in the Hong Kong medical and health industry, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other pharmaceutical sectors [4] - The CSI Innovative Drug Industry Index tracks leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [7] - The CSI Biotechnology Theme Index focuses on leading A-share biotechnology companies, including no more than 50 stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [12]

Group 1 - The pharmaceutical sector experienced a collective rise in the afternoon, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index increasing by 1.5%, the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rising by 1.4%, the CSI 300 Pharmaceutical and Health Index up by 1.1%, the CSI Biotechnology Theme Index increasing by 1.0%, and the CSI Innovative Drug Industry Index rising by 0.9% [1] - China Galaxy Securities stated that the pharmaceutical sector has undergone a prolonged valuation adjustment, and a significant structural repair trend has emerged recently. The innovative drug business development (BD) is expected to continue in the second half of the year, and the global trend of interest rate cuts by major central banks is likely to further enhance the valuation of the innovative drug sector [1] Group 2 - The index focuses on leading companies in the Hong Kong medical and health industry, consisting of 50 stocks from the medical device, biopharmaceutical, chemical drug, and other pharmaceutical sectors [4] - The innovative drug ETF managed by E Fund tracks the CSI Innovative Drug Industry Index, which focuses on leading innovative drug companies in the A-share market, comprising no more than 50 stocks involved in innovative drug research and development [6] - The biotechnology ETF tracks the CSI Biotechnology Technology Index, which focuses on leading biotechnology companies in the A-share market, consisting of no more than 50 stocks involved in gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [11] - The pharmaceutical ETF tracks the CSI 300 Pharmaceutical and Health Index, which focuses on leading companies in the A-share pharmaceutical and health industry, covering various segments of the future health industry, including chemical pharmaceuticals, medical services, and medical devices [13]

Group 1 - Recent industry capital buybacks demonstrate confidence in industry development, with Heng Rui announcing a plan to repurchase A-shares worth 1 to 2 billion yuan for employee stock ownership plans [1] - The performance assessment indicators for the company include innovative drug sales revenue, the number of new molecular entity IND approvals, and the number of innovative drug NDA applications accepted, with unlocking ratios set at 100%, 90%, and 0% [1] - The Vice President of China Biopharmaceutical repurchased 1 million shares, reflecting confidence in the company's development [1] Group 2 - Continuous policy support for the healthy development of the industry is highlighted, with a key leader emphasizing the need for high-quality technological supply and policy support to enhance the biopharmaceutical industry's quality and innovation [1] - On August 11, the Hang Seng Hong Kong Stock Connect Innovative Drug Index was officially adjusted to exclude CXO, becoming a "pure" innovative drug index, which more accurately reflects the overall performance of China's innovative pharmaceutical companies [1] - Historical performance of the index is expected to improve significantly after the exclusion of CXO, with the Hang Seng Innovative Drug ETF (159316) being the only ETF product tracking this index [1]